Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Patient with non-small-cell lung cancer who progressed disease after the previous treatment with EGFR TKI
- Registration Number
- JPRN-jRCT2080223197
- Lead Sponsor
- ippon Boehringer Ingelheim Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 60
1. Aged 20 years or older (Japan only)
2. Pathologically confirmed of advanced and/or metastatic stage IIIb/IV non-small cell carcinoma of lung
3. Activating EGFR mutation
etc.
1. For patient who has been treated with afatinib: last treatment at reduced dose below the assigned dose level (Part A only) or for patient who has been treated with afatinib: at reduced dose less than 30 mg/day (Parts A and B)
2. Patient whose disease progressed on insufficient dose of EGFR TKI immediately prior to study in the opinion of the investigator
3. Part B only: More than 2 prior EGFR TKI treatment regimens
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.